Knowing that CXCL10, on which this review focuses on, is one of the most important factors that amplify the immune response through the requirement of Th1 cells, thus, it was suggested that PDE4 inhibitors are a promising therapeutic option for COVID-19 [66]. This evidence concerns the gene PDE4A and COVID-19.